Medtronic MDT underwent analysis by 6 analysts in the last ... Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work ...

Medtronic shows solid fundamentals, steady growth, and dividend strength despite sector risks and rangebound trading. Read ...

Medtronic's margin inflection from the Diabetes spin-off and strong innovation pipeline support major upside. Find out why ...

I'm not going to claim to be an expert on the healthcare sector, but I am confident that my investment in Medtronic is going to set me up for life, or at least for a lifetime of reliable income.

The FDA is amplifying a recall from Medtronic for its acid reflux testing system, after the company said it received 33 ...

BTIG analysts said today that MiniMed, the Medtronic diabetes business, has some significant pipeline updates.

Shares of Medtronic plc (NYSE:MDT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the sixteen brokerages that are presently covering the firm, Marketbeat.com reports.

Medtronic said it expects the separation to be completed within 18 months, ... Provide specific products and services to you, such as portfolio management or data aggregation.

A Micra AV pacemaker is on display. (Photo by Tang Yanjun/China News Service via Getty Images) Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last ...

Last week, Medtronic announced the intent to separate its diabetes business into a new standalone company. The new company, which remains unnamed, is expected to launch within 18 months.